Skip to main content
Premium Trial:

Request an Annual Quote

John Abeles, Shelly Gunn, Aaron Bensimon

Premium
John Abeles has joined CombiMatrix’s Scientific Advisory Board, CombiMatrix parent company Acacia Research said.
 
Abeles practiced medicine in London before becoming a senior executive in Pfizer, Sterling Drug, and Revlon Health Care. He was a healthcare analyst with Kidder Peabody and later formed MedVest, a healthcare consulting firm.
 
Abeles received his medical degree as well as a degree in pharmacology from the University of Birmingham, UK.
 
Additionally, CombiMatrix has hired Shelly Gunn as a medical director for its CombiMatrix Molecular Diagnostics unit.
 
Gunn earned her BA and Master's degrees from Trinity University. She received her MD and PhD degrees from the University of Texas Health Science Center at San Antonio Graduate School of Biomedical Sciences.
 

Genomic Vision this week said that it had named Aaron Bensimon as president and CEO. Bensimon earned his PhD in molecular biology from the Weizmann Institute of Science in Israel, and has been head of the Genome Stability Unit at the Institut Pasteur since 1994. He developed Genomic Vision’s molecular combing technology at the Statistical Physics Laboratory of the Ecole Normale Supérieure in Paris, and holds 13 patents in the technology.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.